title: Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.
abstract: OBJECTIVE
  The objective of this study was to determine the genes that may be associated with malignant transformation of ovarian endometrioma.
  
  
  METHODS
  Endometriotic epithelial cells were isolated from tissues derived from chocolate cyst linings by laser capture microdissection. A Gene Chip Human Genome U133 Plus 2.0 Array was applied to evaluate levels of gene expression in 3 different groups of epithelial cells: epithelial cells of endometrioma, epithelial cells of endometrioma adjacent to clear cell carcinoma, and epithelial cells of clear cell carcinoma. As a validation assay, real-time reverse transcriptase-polymerase chain reaction and immunohistochemical analyses were performed.
  
  
  RESULTS
  Gene expression analysis identified differential expressions among the 3 groups of epithelial cells. Using the classification of a signaling pathways database, 9 genes (12 gene probes) were selected from among 39 up-regulated genes indicating more than 2-fold higher expression between any comparisons of the 3 groups in the comprehensive microarray. Enhancement of fibroblast growth factor receptor 2 (FGFR2) gene expression was detected by microarray using 3 distinct probes. Gene and protein expression of FGFR2 differed significantly between epithelial cells of endometrioma and the epithelial component of clear cell carcinoma.
  
  
  CONCLUSIONS
  We demonstrated that FGFR2 may play a significant role in the carcinogenesis of endometriosis and thus represents a potential therapeutic target.
authors: Department of Obstetrics and Gynecology, Tottori University Faculty of Medicine, Yonago, Japan. tani4327@med.tottori-u.ac.jp
authors: Fuminori
authors: F
authors: Taniguchi
authors: Hiroaki
authors: H
authors: Itamochi
authors: Tasuku
authors: T
authors: Harada
authors: Naoki
authors: N
authors: Terakawa
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D004715:Endometriosis / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology*; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007124:Immunoenzyme Techniques; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger; C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2